Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

MASSACHUSETTS WILL REQUIRE "NO SUBSTITUTION" STATEMENT IN WRITING as of Nov. 1, in order for a physician to preclude generic substitution. Under the Massachusetts state law entitled "Increasing the Availability of Generic Drugs," a one-line substitution form will replace a two-line form permitting a choice between "dispense as written" or "interchange." Massachusetts prescription pads, after Nov. 1, will have to carry the statement: "Interchange is mandated unless the practitioner writes the words 'no substitution' in this space." The new state law makes Massachusetts the 26th state with a one-line prescription pad format. Other states with legislation mandating the format are Florida, Hawaii, Kentucky and Vermont. The majority of the 26 states with one-line forms, including California, Michigan, Ohio and the District of Columbia, have laws permitting the format. The Massachusetts legislation was enacted on Dec. 16, 1985. It is part of Chapter 582 of the state Acts of 1985. According to the Massachusetts Department of Public Health, the two lobbying groups pushing for the change were Mass PIRG (Public Interest Research Group) and the Legislative Council of Older Americans.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts